Finally, we further validated our results in PCLS from end-stage IPF tissue explants and found that treatment with VP reduced LOX expression as well as CTGF, WISP1 and FN1 in IPF tissue (Fig. 7E, F). Here, FN1 is linked to idiopathic pulmonary fibrosis.